Trilostane Chemical Properties |
Melting point |
264 °C |
alpha |
D25 +137.4° (c = 1 in pyridine) |
Boiling point |
467.02°C (rough estimate) |
density |
1.1213 (rough estimate) |
refractive index |
1.5614 (estimate) |
storage temp. |
2-8°C |
solubility |
DMSO: ≥17mg/mL |
pka |
8.57±0.70(Predicted) |
form |
powder |
color |
white to tan |
CAS DataBase Reference |
13647-35-3(CAS DataBase Reference) |
EPA Substance Registry System |
Trilostane (13647-35-3) |
|
Trilostane Usage And Synthesis |
treatment of Cushing's syndrome |
Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome and primary hyperaldosteronism. These are both disorders where excess amounts of corticosteroid hormones are produced in the body. Corticosteroids are essential for the body to make use of carbohydrates, fats and proteins and for a normal response to stress. They are also necessary for the regulation of salt and water balance in the body. Trilostane helps prevent the production of corticosteroids, controlling the symptoms associated with these disorders.
Trilostane can also be useful in the treatment of breast cancer that has relapsed in women who have gone through menopause. |
Uses in dogs |
Trilostane was withdrawn from the United States market in April 1994. However, it was approved in 2008 for the treatment of Cushing's disease (hyperandrenocorticism) in dogs.
It is also the first drug approved to treat both pituitary-and adrenal-dependent Cushing's in dogs.
1. has kidney or liver disease.
2. takes certain medications used to treat heart disease.
3. pregnant.
4. taking other medicines, including those available to buy without a prescription, herbal or complementary medicines.
5. had an allergic reaction to this or any other medicine. |
|
|